Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13206384 | 0.93 | LMNA (0.61) | LMNAHCAR3MAPTL3MBTL1MAPK1 | |
| SCHEMBL10981845 | 0.87 | HCAR3 (0.55) | LMNAHCAR3MAPTMAPK1BCHE | |
| SCHEMBL9796711 | 0.81 | HCAR3 (0.56) | LMNAHCAR3MAPTL3MBTL1MAPK1 | |
| SCHEMBL13206385 | 0.81 | MAPT (0.51) | LMNAHCAR3MAPTL3MBTL1MAPK1 | |
| SCHEMBL428455 | 0.79 | HCAR3 (0.53) | LMNAHCAR3MAPTL3MBTL1MAPK1 | |
| SCHEMBL16406347 | 0.79 | PGK1 (0.53) | LMNAHCAR3MAPTL3MBTL1MAPK1 | |
| SCHEMBL3449782 | 0.76 | LMNA (0.51) | LMNAHCAR3MAPTL3MBTL1MAPK1 | |
| SCHEMBL13401684 | 0.75 | HCAR3 (0.64) | LMNAHCAR3MAPTL3MBTL1MAPK1 | |
| SCHEMBL23418074 | 0.74 | HCAR3 (0.47) | LMNAHCAR3MAPTBCHEACHE | |
| SCHEMBL25682292 | 0.74 | HCAR3 (0.47) | LMNAHCAR3MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115232-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-04-28 | — | — | US | disclosed |
| US-20090088484-A1 | NITRIC OXIDE (NO)-RELEASING POLYMERS AND COMPOUNDS AND USES THEREOF | CENTRAL MICHIGAN UNIVERSITY | 2009-04-02 | — | — | US | disclosed |
| US-20080260797-A1 | METHODS OF TREATING DISEASE WITH NITRIC OXIDE (NO)-RELEASING POLYMERS AND SOLUBLE NO-RELEASING NITROSAMINES | CENTRAL MICHIGAN UNIVERSITY | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088484-A1 | NITRIC OXIDE (NO)-RELEASING POLYMERS AND COMPOUNDS AND USES THEREOF | NOS2, NOS3, NOS1 | LMNA 2914/4885HCAR3 201/4885MAPT 2614/4885 |
| US-20160115232-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | FCGR2A, CD22, FCGR3B | LMNA 4746/4885HCAR3 259/4885MAPT 1854/4885 |
| US-20080260797-A1 | METHODS OF TREATING DISEASE WITH NITRIC OXIDE (NO)-RELEASING POLYMERS AND SOLUBLE NO-RELEASING NITROSAMINES | NOS2, NOS1, NOS3 | LMNA 2252/4885HCAR3 280/4885MAPT 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.